Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
Open accessThe DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index; 48 of the 126 sources its claims cite were checked for support.
Abstract
Improvements in sensor accuracy, greater convenience and ease of use, and expanding reimbursement have led to growing adoption of continuous glucose monitoring (CGM). However, successful utilization of CGM technology in routine clinical practice remains relatively low. This may be due in part to the lack of clear and agreed-upon glycemic targets that both diabetes teams and people with diabetes can work toward. Although unified recommendations for use of key CGM metrics have been established in three separate peer-reviewed articles, formal adoption by diabetes professional organizations and guidance in the practical application of these metrics in clinical practice have been lacking. In February 2019, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address this issue. This article summarizes the ATTD consensus recommendations for relevant aspects of CGM data utilization and reporting among the various diabetes populations.
Overview
CoChat Summary
TL;DR
An international ATTD consensus panel recommends standardized continuous glucose monitoring (CGM) time-in-range targets to complement A1C for type 1/type 2 diabetes, older/high-risk individuals, and pregnancy. It defines target TIR, TBR, and TAR cutpoints and cites evidence linking TIR to A1C and diabetes complications.
Key findings
- For type 1/type 2 diabetes, the panel recommends TIR 70–180 mg/dL >70% (>16 h 48 min), TBR <70 mg/dL <4% (<1 h), TBR <54 mg/dL <1% (<15 min), TAR >180 mg/dL <25% (<6 h), and TAR >250 mg/dL <5% (<1 h 12 min). For older/high-risk individuals, TIR target is >50% (>12 h), TBR <70 mg/dL <1% (<15 min), and TAR >250 mg/dL <10% (<2 h 24 min).
- For pregnancy in type 1 diabetes, the target range is 63–140 mg/dL (3.5–7.8 mmol/L), with TIR >70% (>16 h 48 min), TBR <63 mg/dL <4% (<1 h), TBR <54 mg/dL <1% (<15 min), and TAR >140 mg/dL <25% (<6 h); pregnancy type 2/GDM targets were not included because of limited evidence.
- TIR relates to A1C: TIR 70% and 50% corresponded with A1C approximately 7% (53 mmol/mol) and 8% (64 mmol/mol), respectively; every 10% increase in TIR corresponded to about 0.5% (5.5 mmol/mol) A1C reduction in Beck et al. (n=545 type 1 diabetes) and about 0.8% (8.7 mmol/mol) in Vigersky et al. (n=1,137 type 1/type 2).
- In DCCT data, hazard for retinopathy progression increased by 64% for each 10% reduction in TIR, and microalbuminuria development increased by 40%; in 3,262 people with type 2 diabetes, more advanced diabetic retinopathy was associated with less time in target range. The panel also recommends 14 days of CGM data, >70% CGM active, and %CV target <36% (some studies suggest <33%).
Methods
- Consensus process: in February 2019, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes expert in CGM; subgroups reviewed literature and presented evidence-based recommendations to the full panel for voting.
- Data/sample: no new primary trial was conducted; the paper synthesizes cited studies, including Beck et al. (n=545 type 1 diabetes), Vigersky et al. (n=1,137 type 1/type 2), Lu et al. (3,262 type 2 diabetes), DCCT analyses, and pregnancy CGM studies.
- Main analysis: narrative evidence synthesis and expert consensus on CGM metrics, time-in-range cutpoints, and standardized Ambulatory Glucose Profile reporting; no formal meta-analysis or systematic review is described.
Limitations
- The paper states that long-term trials demonstrating how CGM metrics relate to and/or predict clinical outcomes have not been conducted, and the evidence is suggestive; pregnancy percentages are based on limited evidence and more research is needed.
- The paper states there is no evidence regarding time in range for older and/or high-risk individuals, and CGM targets for women with GDM or type 2 diabetes in pregnancy were not included because of lack of evidence.
- Evident from the text: recommendations are consensus/expert opinion rather than a systematic review, and the consensus meeting/manuscript was funded by ATTD with support from multiple industry sponsors; many panel members report industry consulting, speaking, research, or advisory relationships.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
16 Valid · 14 Not valid · 24 Not checked · 13 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In individuals with type 1 diabetes, correlations are weaker for hypoglycemia and glycemic variability; however, these correlations have not been shown to increase with longer sampling periods (42).”
What the sources say
- Disputedcites [42] 41. Xing D, Kollman C, Beck RW, et al. Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring. Diabetes Technol Ther 2011;13:351-358. sourceExperimental — accuracy not yet measured
In type 1 diabetes, the Results (Table 2; page unavailable) show weaker correlations for hypoglycemia and glycemic variability than for mean glucose at 15 days. But they also show that both correlations increase as sampling extends from 3 to 15 days, contrary to the citing sentence’s claim that an increase with longer sampling has not been shown. The paper does not frame this analysis as >70% CGM use over 14 days. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In individuals with type 1 diabetes, correlations are weaker for hypoglycemia and glycemic variability; however, these correlations have not been shown to increase with longer sampling periods (42).”
What the sources say
- Disputedcites [42] 41. Xing D, Kollman C, Beck RW, et al. Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring. Diabetes Technol Ther 2011;13:351-358. sourceExperimental — accuracy not yet measured
The Results (Table 2; page unavailable) show that correlations with the full three-month data increased as sampling lengthened for both hypoglycemia and glycemic variability. From 3 to 15 days, r² rose from 0.32 to 0.66 for values ≤70 mg/dL and from 0.36 to 0.70 for coefficient of variation—the opposite of the attributed claim. (LLM, conf=0.93)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The first longitudinal CGM data demonstrated a 13percentage point increase in TIR (43% to 56% TIR 70-140 mg/dL [3.9-7.8 mmol/L]) (61).”
What the sources say
- Disputedcites [61] 62. Stewart ZA, Wilinska ME, Hartnell S, et al. Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. N Engl J Med. 2016;375(7):644-654. sourceExperimental — accuracy not yet measured
The Study Outcomes report different CGM time-in-range results: 59.5% to 74.7% overnight and 56.8% to 66.3% over 24 hours with closed-loop therapy. The paper defines its target range as 63–140 mg/dL, not 70–140 mg/dL; it does not report the claimed increase from 43% to 56%. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Numerous studies have demonstrated significant clinical benefits of CGM use in people with diabetes regardless of insulin delivery method (1-15).”
What the sources say
- Not checked — no full text of the sourcecites [1] 1. Lind M, Polonsky W, Hirsch IB. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA 2017;317(4):379-387 source
- Partly supportedcites [2] 2. Aleppo G, Ruedy KJ, Riddlesworth TD, et al. REPLACE-BG: A randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well-controlled type 1 diabetes. Diabetes Care 2017;40(4):538-545. sourceExperimental — accuracy not yet measured
The Introduction reports that several randomized trials found CGM benefits, including reduced HbA1c and hypoglycemia, particularly in adults with type 1 diabetes. But the Conclusions say this trial included only insulin-pump users; extending its results to people using injections is described as reasonable, not demonstrated. The paper therefore does not establish benefits regardless of insulin delivery method or across all people with diabetes. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [3] 3. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA 2017; 317:371-378. source
- Not checked — no full text of the sourcecites [4] 4. Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med 2017;167:365-374. source
- Not checked — no full text of the sourcecites [5] 5. Polonsky WH, Hessler D, Ruedy KJ, Beck RW, for the DIAMOND Study Group. The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes: further findings from the DIAMOND randomized clinical trial. Diabetes Care 2017; 40:736-741. source
- Supportedcites [6] 6. ϲ͘ ŠŽƵƉĂů J͕ PĞƚƌƵǎĞůŬŽǀĄ L͕ FůĞŬĂē M͕ Ğƚ Ăů͘ CŽŵƉĂƌŝƐŽŶ ŽĨ ĚŝĨĨĞƌĞŶƚ ƚƌĞĂƚŵĞŶƚ ŵŽĚĂůŝƚŝĞƐ ĨŽƌ type 1 diabetes, including sensor-augmented insulin regimens, in 52 weeks of follow-up: a COMISAIR study. Diabetes Technol Ther. 2016;18(9):532-538. source
The Discussion reports significant glycemic benefits from real-time CGM that were comparable with pump (CSII) and injection (MDI) therapy. The study concerns people with type 1 diabetes. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [7] 7. van Beers CA, DeVries JH, Kleijer SJ, et al. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, openlabel, crossover trial. Lancet Diabetes Endocrinol. 2016;4(11):893-902. source
- Not checked — no full text of the sourcecites [8] 8. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kr ger J, Weitgasser R. Novel glucose-sensing technology and hypoglycemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet 2016;388:2254-2263. source
- Partly supportedcites [9] 9. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulintreated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther 2017;8(1):55-73. sourceExperimental — accuracy not yet measured
The Results report significant reductions in hypoglycemic events with flash glucose monitoring in adults with insulin-treated type 2 diabetes, supporting a clinical benefit. The Results also state that 95% of participants used an insulin pen or syringe and 5% used continuous subcutaneous insulin infusion; the paper does not establish that the benefit held regardless of insulin delivery method. No page numbers are available in our copy. (LLM, conf=0.85)
- Partly supportedcites [10] 10. Choudhary P, Olsen BS, Conget I, et al. Hypoglycemia prevention and user acceptance of an insulin pump system with predictive low glucose management. Diabetes Technol Ther 2016;18(5):288-291. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says the CGM-based MiniMed 640G pump system can help patients with type 1 diabetes avoid hypoglycemia. But this short, uncontrolled study examined a predictive pump-suspension system, not CGM use regardless of insulin delivery method; it does not establish a benefit across delivery methods or isolate the benefit of CGM itself. (LLM, conf=0.88)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A1C is currently recognized as the key surrogate marker for the development of longterm diabetes complications in people with type 1 and type 2 diabetes and has been used the primary endpoint for many CGM studies (1; 3; 4; 6; 32; 33).”
What the sources say
- Not checked — no full text of the sourcecites [1] 1. Lind M, Polonsky W, Hirsch IB. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA 2017;317(4):379-387 source
- Not checked — no full text of the sourcecites [3] 3. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA 2017; 317:371-378. source
- Not checked — no full text of the sourcecites [4] 4. Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med 2017;167:365-374. source
- Could not verifycites [6] 6. ϲ͘ ŠŽƵƉĂů J͕ PĞƚƌƵǎĞůŬŽǀĄ L͕ FůĞŬĂē M͕ Ğƚ Ăů͘ CŽŵƉĂƌŝƐŽŶ ŽĨ ĚŝĨĨĞƌĞŶƚ ƚƌĞĂƚŵĞŶƚ ŵŽĚĂůŝƚŝĞƐ ĨŽƌ type 1 diabetes, including sensor-augmented insulin regimens, in 52 weeks of follow-up: a COMISAIR study. Diabetes Technol Ther. 2016;18(9):532-538. sourceExperimental — accuracy not yet measured
The Prespecified outcomes section (page unavailable) identifies HbA1c as this type 1 diabetes study’s primary endpoint. Neither that section nor the Discussion passages establish that A1C is the key surrogate marker for long-term complications in people with both type 1 and type 2 diabetes. Searches for that surrogate-marker relationship and for complications found no passage stating it. (LLM, conf=0.72)
- Partly supportedcites [33] 32. Battelino T, Conget I, Olsen B, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia 2012;55(12):3155-3162. sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) links near-normal glycaemia with reduced complication risk in type 1 diabetes, and Methods > Outcome measure (page unavailable) uses HbA1c as this trial’s primary endpoint. The paper does not establish HbA1c as the key surrogate marker for long-term complications in both type 1 and type 2 diabetes. (LLM, conf=0.81)
- Could not verifycites [32] 31. Novodvorsky P, Bernjak A, Chow E, et al. Diurnal differences in risk of cardiac arrhythmias during spontaneous hypoglycemia in young people with type 1 diabetes. Diabetes Care 2017;40:655 ʹ 662. sourceExperimental — accuracy not yet measured
The Baseline Assessment section says HbA1c was measured at the start of monitoring, but does not describe it as a surrogate marker for long-term complications. The Research Design and Methods section examines arrhythmias during hypoglycemia, not A1C as a primary endpoint in CGM studies. Searches for the surrogate-marker and primary-endpoint claims found no supporting passage in our copy. (LLM, conf=0.76)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
37 more claims · 16 with their cited sources checked
Create a free account to see all 67 claims and to verify the 4 references still open.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 13
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“With the advent of newer studies of CGM in noninsulin‐treated individuals and increasing uptake, the utility of CGM is progressively being endorsed in this population.”
From Continuous glucose monitoring in noninsulin‐treated type 2 diabetes: A critical review of reported trials with an updated systematic review and meta‐analysis of randomised controlled trials (2025) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypoglycaemia is associated with an increased risk of vascular events, explaining recent consensus advocating hypoglycaemic exposure at <1% (i.e.<15 min/day) in individuals at high CV risk.137,138”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [138]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Considering the older age of participants and comorbid conditions reported, the mean HbA1c, GMI, TIR, and TBR results (8.0%, 7.6%, 56%, and 1.0% at 6 months, respectively) demonstrate close adherence to established glycemic targets (23, 24, 38).”
From Observed Glycemic and Psychosocial Benefits in the Prospective Bigfoot Unity Real World Study: A 6-Month Analysis (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Avaiable data suggest that such systems can increase TIR and reduce hypoglycemia in patients with DGP, with improvements comparable to those observed in individuals without gastrointestinal complications, although data remain limited and largely observational [153–157].”
From Diabetic gastroparesis: pathophysiology and impact on insulin timing choices (2026) · cites this paper as [156]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A subsequent international consensus defined targets for most of the measures on the AGP that would correspond to individualized HbA 1c targets (193).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [193]
Experimental — accuracy not yet measured
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ FIGURES / TABLES · p. 4
“2 Figures / 3 Tables”
§ Relationship Between TIR and A1C · p. 15
“Table 4. Estimate of A1C for a given TIR level based on type 1 diabetes and type 2 diabetes studies”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Time in Ranges · p. 11
“Table 4. Consensus guidance on cutpoints for assessment of glycemic control: Pregnancy”
§ Relationship Between TIR and A1C · p. 15
“Table 4. Estimate of A1C for a given TIR level based on type 1 diabetes and type 2 diabetes studies”
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
Self-citationState of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
Foster, N. C., Beck, R. W., Miller, K. M., Clements, M. A., Rickels, M. R., DiMeglio, L. A., Maahs, D. M., Tamborlane, W. V., Bergenstal, R., Smith, E., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0384 · Cited by 1,907
Self-citationIsmail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389
Self-citationBeck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., McGill, J. B., Polonsky, W., et al. (2017) · JAMA · doi:10.1001/jama.2016.19975 · Cited by 1,185 · cited 1×
“A1C is currently recognized as the key surrogate marker for the development of long-termdiabetes complications in people with type 1 and type 2 diabetes and has been used as the primary end point for many CGM studies (1,3,4,6,33,34).”
BackgroundSelf-citationBolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J., & Weitgasser, R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31535-5 · Cited by 893
Cited by
Items 801–900 of 3,959
Beck, R. W., & Bergenstal, R. M. (2021) · Diabetes Spectrum · doi:10.2337/ds20-0090 · Cited by 23
Self-citationAddala, A., Zaharieva, D. P., Gu, A., Prahalad, P., Scheinker, D., Buckingham, B. A., Hood, K. K., & Maahs, D. M. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab522 · Cited by 23
Self-citationPiccini, B., Pessina, B., Pezzoli, F., et al. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13326 · Cited by 21
Zone-MPC Automated Insulin Delivery Algorithm Tuned for Pregnancy Complicated by Type 1 Diabetes
Özaslan, B., Deshpande, S., Doyle, F. J., & Dassau, E. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.768639 · Cited by 24
“Pregnancy with T1D is one of the conditions that necessitate customization of CLC systems due to significant changes in the glucose-insulin metabolism with advancing gestation (8) and tight glucose control targets throughout gestation (9).”
BackgroundSelf-citationKompala, T., Wong, J. C., & Neinstein, A. B. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221088267 · Cited by 28
Park, S. H., Yao, J., Chua, X. H., CHANDRAN, S. R., Gardner, D. S.-L., Khoo, C. M., Müller‐Riemenschneider, F., Whitton, C., & van Dam, R. M. (2022) · Nutrients · doi:10.3390/nu14020366 · Cited by 25
“The selected indices were suggested to be core CGM metrics in clinical practice, according to an international consensus by the Advanced Technologies and Treatments for Diabetes Congress in 2019 [30].”
MethodXu, Y., Bergenstal, R. M., Dunn, T. C., Ram, Y., & Ajjan, R. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14763 · Cited by 23
“Results: The mean age (range) was 30 years (8-72) with 94 younger than 19 years,”
BackgroundSelf-citationNallicheri, A., Close Concerns, S. F., Mahoney, K. M., Close Concerns, S. F., Gutow, H. A., Close Concerns, S. F., Bellini, N. J., & Isaacs, D. M. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.1.27 · Cited by 24
“39 In keeping with the International TIR Guidelines, dialogue on CGM-derived metrics (TIR, time below range and time above range) and improvements or challenges since the last patient–clinician interaction can improve glycaemic outcomes, help with goal setting and guide the timing of follow-up appointments.(40)”
BackgroundTime in Range and Pregnancy Outcomes in People with Diabetes Using Continuous Glucose Monitoring
Bartal, M. F., Cornthwaite, J. A. A., Ghafir, D., Ward, C., Ortíz, G., Louis, A., Cornthwaite, J., Chauhan, S. S. P., & Sibai, B. M. (2022) · American Journal of Perinatology · doi:10.1055/a-1904-9279 · Cited by 24
Assessment of the Glucose Management Indicator Using Different Sampling Durations
Bailey, R. J., Calhoun, P. M., Bergenstal, R. M., & Beck, R. W. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0284 · Cited by 22
Self-citationFeig, D. S. (2022) · Diabetes Care · doi:10.2337/dci21-0027 · Cited by 25
Patience, M., Janssen, X., Kirk, A. F., McCrory, S., Russell, E., Hodgson, W., & Crawford, M. M. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20054363 · Cited by 29
“Therefore, the aim of this study is to conduct a systematic review of quantitative and qualitative studies to comprehensively investigate 24-hour movement behaviours (individual and/or combined) and their impact on primary (glycated haemoglobin (HbA1c) and continuous glucose monitoring (CGM) metrics and quality of lif…”
BackgroundInfluentialZhang, X., Zhang, Y., Luo, L., Le, Y., Li, Y., Yuan, F., Wu, Y., & Xu, P. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s400119 · Cited by 22
“Moreover, although a prolonged duration (2–4 weeks) of CGM is recommended by current guidelines to reduce the likelihood of statistical bias, we only collected the CGM data for 7 days due to restrictions related to the CGM recorder.(36) Additionally, the impact of dietary factors and exercise on GV cannot be underesti…”
BackgroundAl‐Sofiani, M. E., Alharthi, S. K., Albunyan, S., Alzaman, N. S., Klonoff, D. C., & Alguwaihes, A. M. (2024) · Diabetes Care · doi:10.2337/dc23-1968 · Cited by 25
Diabetes technology in people with diabetes and advanced chronic kidney disease
Galindo, R. J., Soliman, D., Cherñavvsky, D. R., & Rhee, C. M. (2024) · Diabetologia · doi:10.1007/s00125-024-06244-y · Cited by 25
“Based on expert opinion, and given the higher risk of hypoglycaemia, the recommended TIR for individuals with advanced CKD or with ESKD on dialysis is >50%, with a TBR of 1% [30, 31].”
BackgroundInfluentialUrakami, T., Yoshida, K., Kuwabara, R., Mine, Y., Aoki, M., Suzuki, J., & Morioka, I. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej20-0193 · Cited by 24
“For the purposes of this study, we specified TIR (70–180 mg/dL), TBR (<70 mg/dL), and TAR (>180 mg/dL) on the basis of previously reported CGM metrics [1].”
BackgroundMethodInfluentialSelf-citationKriventsov, S., Lindsey, A., & Hayeri, A. (2020) · JMIR Diabetes · doi:10.2196/18660 · Cited by 23
“BCT: Bio Conscious Technologies, Inc BGLP: Blood Glucose Level Prediction CGM: continuous glucose monitoring GMI: glucose management indicator HBGI: high blood glucose risk index LBGI: low blood glucose risk index RMSE: root mean square error SVM: support vector machine T1DM: type 1 diabetes mellitus TIR: time in eugl…”
MethodLi, J., Li, Y., Ma, W., Liu, Y., Yin, X., Xie, C., Bai, J., & Zhang, M. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.09.028 · Cited by 23
Smith, K., Davies, K. A. B., Stevenson, E., & West, D. J. (2020) · Frontiers in Nutrition · doi:10.3389/fnut.2020.587843 · Cited by 24
“CGM allows for the detailed assessment of intra- and inter-daily glycaemic excursions under free-living conditions (66, 67).”
BackgroundInfluentialŠumník, Z., Pavlíková, M., Pomahačová, R., Venháčová, P., Petruželková, L., Škvor, J., Neumann, D., Vosáhlo, J., Konečná, P., Čížek, J., et al. (2021) · Pediatric Diabetes · doi:10.1111/pedi.13184 · Cited by 23
The frequency of intermittently scanned glucose and diurnal variation of glycemic metrics
Hansen, K. W., & Bibby, B. M. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211019382 · Cited by 20
“1464 Journal of Diabetes Science and Technology 16(6)”
BackgroundInfluentialVan Name, M. A., Kanapka, L. G., DiMeglio, L. A., Miller, K. M., Albanese-O’Neill, A., Commissariat, P., Corathers, S. D., Harrington, K. R., Hilliard, M. E., Anderson, B. J., et al. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221084667 · Cited by 20
Self-citationKozinetz, R. M., Berikov, V., Semenova, J. F., & Klimontov, V. V. (2024) · Diagnostics · doi:10.3390/diagnostics14070740 · Cited by 27
“Other widely accepted metrics are time above target glucose range and time below target glucose range [30].”
BackgroundUrakami, T., Terada, H., Tanabe, S., Mine, Y., Aoki, M., Aoki, R., Suzuki, J., & Morioka, I. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14303 · Cited by 22
“The frequencies of glycemic targets of TIR > 70% and TBR 4%, proposed by the ATTD panel 8, 9 , were 24.1 and 53.0%, respectively.”
BackgroundMethodInfluentialSelf-citationHasan, S. S., Kow, C. S., Bain, A., Kavanagh, S., Merchant, H. A., & Hadi, M. A. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1837114 · Cited by 26
“0 mmol/L, and <25% of time glucose readings >10mmol/L, in a 24-hour period [48].”
BackgroundFull closed loop open‐source algorithm performance comparison in pigs with diabetes
Lal, R., Maikawa, C. L., Lewis, D. M., Baker, S. W., Autzen, A. A. A., Roth, G. A., Gale, E. C., Stapleton, L. M., Mann, J. L., Yu, A. C., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.387 · Cited by 22
Self-citationMiller, E. M., & Midyett, L. K. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0192 · Cited by 25
“21 Users scan the sensor with the device reader to obtain their glucose data.”
Dovč, K., Name, M. A. V., Bizjan, B. J., Rusak, E., Piona, C. A., Mutlu, G. Y., Mentink, R., Frontino, G., Macedoni, M., Ferreira, S., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14607 · Cited by 21
Self-citationHolzer, R., Schulte-Körne, B., Seidler, J., Predel, H., & Brinkmann, C. K. (2021) · Nutrients · doi:10.3390/nu13124322 · Cited by 27
“An important parameter for assessing health risks in diabetes mellitus is the time in target range (TIR), expressed as the percentage of readings/time within the glucose range of 70–180 mg/dL [26,27].”
BackgroundAsh, G. I., Gueorguieva, R. V., Barnett, N. P., Wang, W., Robledo, D. S., DeMartini, K. S., Pittman, B. P., Redeker, N. S., O’Malley, S. S., & Fucito, L. M. (2022) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14804 · Cited by 23
Freckmann, G., Schauer, S., Beltzer, A., Waldenmaier, D., Buck, S., Baumstark, A., Jendrike, N. R. M., Link, M., Zschornack, E., Haug, C., et al. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221113341 · Cited by 24
“Nevertheless, all participants reached > 90% time in the target range of 70-180 mg/dL which clearly exceeds the target recommended by Battelino et al 22 for diabetes patients ( > 70% time in the target range 70-180 mg/dL).”
BackgroundMario, C. D., Genovese, S., Lanza, G. A., Mannucci, E., Marenzi, G., Sciatti, E., Pitocco, D., the Expert Panel Group, Avogaro, A., Bertuzzi, F., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01598-2 · Cited by 26
“In addition, the availability of monitoring data in a simple and standardized format, such as the Ambulatory Glucose Profile [11], can facilitate their use in routine clinical practice, enhancing treatment adjustments and improving patient education.”
BackgroundEichenlaub, M., Stephan, P., Waldenmaier, D., Pleus, S., Rothenbühler, M., Haug, C., Hinzmann, R., Thomas, A., JENDLE, J. H., Diem, P., et al. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221134639 · Cited by 23
“29 While these ranges are well-established and can be used to characterize the status of glycemic control, they are not ideal for assessing the accuracy of a CGM system.”
Polonsky, W. H., Fortmann, A. L., Soriano, E. C., Guzman, S. J., & Funnell, M. M. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0419 · Cited by 20
Time above range for predicting the development of type 2 diabetes
Marco, A., Pazos-Couselo, M., Moreno-Fernández, J., Díez‐Fernández, A., Alonso‐Sampedro, M., Fernández‐Merino, C., González‐Quintela, A., & Gudé, F. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1005513 · Cited by 26
“Fasting plasma glucose, mg/dL (SD) 87 (10) 105 (12) <0.”
BackgroundOriot, P., kurz, N. K. D., Ponchon, M., Weber, E., Colin, I. M., & Philips, J. (2022) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2022.100125 · Cited by 20
Li, C., Ma, X., Lu, J., Tao, R., Yu, X., Mo, Y., Lu, W., Bao, Y., Zhou, J., & Jia, W. (2022) · Frontiers of Medicine · doi:10.1007/s11684-022-0955-9 · Cited by 20
Self-citationContinuous Glucose Monitoring in Dogs and Cats
Baldo, F. D., & Fracassi, F. (2023) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2023.01.008 · Cited by 26
Bitar, G., Cornthwaite, J. A. A., Sadek, S., Ghorayeb, T., Daye, N., Nazeer, S. A., Ghafir, D., Cornthwaite, J., Chauhan, S. P., Sibai, B. M., et al. (2023) · American Journal of Perinatology · doi:10.1055/s-0043-1764208 · Cited by 25
Cho, S. H., Kim, S., Lee, Y., Jin, S., Hur, K. Y., Kim, G., & Kim, J. H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1165471 · Cited by 29
Phillips, N. E., Collet, T., & Naef, F. (2023) · Cell Reports Methods · doi:10.1016/j.crmeth.2023.100545 · Cited by 26
Vascimini, A., Saba, Y., Baskharoun, F., Crooks, K., Huynh, V., Wasson, S., Wright, E., Bullers, K., Franks, R. B., Carris, N. W., et al. (2023) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2023.07.010 · Cited by 29
MiniMed TM 780G Advanced Hybrid Closed-Loop System Study in Pregnant Women with Type 1 Diabetes
Guibert, C., Amoura, L., Rakotoarisoa, L., Plat, F., Sonnet, E., Lablanche, S., Tréglia, C., Sarde, E., Leca, V., Rimareix, F., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0267 · Cited by 23
Sherr, J. L., Bergford, S., Gal, R. L., Clements, M. A., Patton, S. R., Calhoun, P. M., Beaulieu, L. C., & Riddell, M. C. (2024) · Diabetes Care · doi:10.2337/dc23-2212 · Cited by 23
Schiaffini, R., Lumaca, A., Martino, M., Rapini, N., Deodati, A., Amodeo, M. E., Ciampalini, P., Matteoli, M. C., Pampanini, V., & Cianfarani, S. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3826 · Cited by 23
“9 Time in range (TIR) 3.9–10.0 mmol/L (70–180 mg/dL) 10,11 has quickly been established as a useful metric for patients using CGM systems and reaching a TIR of 70% or more allows to achieve a target HbA1c of 53 mmol/mol (7.0%).”
InfluentialThe use of technology in type 2 diabetes and prediabetes: a narrative review
Liarakos, A. L., Lim, J. Z. M., Leelarathna, L., & Wilmot, E. G. (2024) · Diabetologia · doi:10.1007/s00125-024-06203-7 · Cited by 27
“Cognitive impairment, multimorbidity and sensory deficits due to increasing age are important challenges in this group [102, 103], while the significance of reducing hypoglycaemia is emphasised in international recommendations [90].”
BackgroundModern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care
Caturano, A., Galiero, R., Rocco, M. P., Tagliaferri, G., Piacevole, A., Nilo, D., Lorenzo, G. D., Sardu, C., Vetrano, E., Monda, M., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12092039 · Cited by 28
“It is crucial to avoid hypoglycemia, as it is associated with an increased risk of vascular events [151,152].”
BackgroundSuzuki, D., Yamada, H., Yoshida, M., Funazaki, S., Amamoto, M., Morimoto, J., & Hara, K. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13240 · Cited by 20
Viñals, C., Beneyto, A., José, J., Furió-Novejarque, C., Bertachi, A. H., Bondía, J., Vehí, J., Conget, I., & Giménez, M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa562 · Cited by 26
The Ambulatory Glucose Profile: Opportunities for Enhancement
Rodbard, D. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0524 · Cited by 24
Self-citationA Virtual Training Program for the Tandem t:slim X2 Insulin Pump: Implementation and Outcomes
Pinsker, J. E., Singh, H., McElwee-Malloy, M., Constantin, A., LEAS, S. A., Kriegel, K., & HABIF, S. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0602 · Cited by 21
Rethinking Carbohydrate Intake and Time in Range in Children and Adolescents with Type 1 Diabetes
Cherubini, V., Marino, M., Marigliano, M., Maffeis, C., Zanfardino, A., Rabbone, I., Giorda, S., Schiaffini, R., Lorubbio, A., Rollato, A. S., et al. (2021) · Nutrients · doi:10.3390/nu13113869 · Cited by 23
“If confirmed, these data could have implications in clinical practice, because small changes in diet could increase the percentage of TIR in children and adolescents with T1D.”
BackgroundMethodInfluentialAldibbiat, A. M., Alqashami, A., & Hussain, S. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13720 · Cited by 20
Anticoagulation protocol and early prosthetic valve thrombosis.
Talwar, S., Kapoor, C. K., Devagourou, V., & Kumar, A. S. (2004) · PubMed · Cited by 24
Is It Time to Replace Time-in-Range with Time-in-Tight-Range? Maybe Not
Beck, R. W. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0602 · Cited by 23
Self-citationAllo Beta Cell transplantation: specific features, unanswered questions, and immunological challenge
Caldara, R., Tomajer, V., Monti, P., Sordi, V., Citro, A., Chimienti, R., Gremizzi, C., Catarinella, D., Tentori, S., Paloschi, V., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1323439 · Cited by 21
“Hyperglycemia aversiveness”: investigating an overlooked problem among adults with type 1 diabetes
Polonsky, W. H., Fortmann, A. L., Price, D., & Fisher, L. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107925 · Cited by 19
Grammes, J., Schmid, S., Bozkurt, L., Heinemann, L., Hess, G., Kubiak, T., Küstner, E., Priesterroth, L., Stahl, C., Holl, R. W., et al. (2023) · Diabetic Medicine · doi:10.1111/dme.15261 · Cited by 24
“17 Even though there is a lack of evidence for time in range in older individuals, numerous previous studies have emphasized the elevated risk for hypoglycaemia in this population.”
BackgroundSelf-citationContinuous glucose sensor accuracy: beyond the headline metric
Oliver, N. S., Reddy, M., & Leelarathna, L. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00245-6 · Cited by 23
Moscoso-Vásquez, M., Colmegna, P. H., Barnett, C. L., Fuller, M. R., Koravi, C. L. K., Brown, S. A., DeBoer, M. D., & Breton, M. D. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0315 · Cited by 22
Laesser, C. I., Piazza, C. D., Schorno, N., Nick, F., Kastrati, L., Züger, T., Barnard-Kelly, K. D., Wilinska, M. E., Nakas, C. T., Hovorka, R., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06319-w · Cited by 31
Self-citationDeshmukh, H., Wilmot, E. G., Choudhary, P., Ssemmondo, E., Barnes, D., Walker, N., Walton, C., Ryder, R. E. J., & Sathyapalan, T. (2025) · Diabetes Care · doi:10.2337/dc24-1833 · Cited by 26
Trajectories of Sleep Duration, Sleep Onset Timing, and Continuous Glucose Monitoring in Adults
Shen, L., Li, B., Gou, W., Liang, X., Zhong, H., Xiao, C., Shi, R., Miao, Z., Yan, Y., Fu, Y., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.0114 · Cited by 23
Zaharieva, D. P., Teng, J. H., Ong, M. L., Lee, M. H., Paldus, B., Jackson, L., Houlihan, C. A., Shub, A., Tipnis, S., Cohen, O., et al. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0073 · Cited by 25
“8 A systematic review of pooled normal pregnancy glucose data from studies conducted in the USA and Europe showed fasting glucose of 70 – 7 mg/dL, 1 h postprandial glucose of 108 – 13 mg/dL, 2 h postprandial glucose of 99 – 10 mg/dL, F I G .”
Time in Range as a Research Outcome Measure
Timmons, J. G., Boyle, J. G., & Petrie, J. R. (2021) · Diabetes Spectrum · doi:10.2337/ds20-0097 · Cited by 23
Conget, I., Mangas, M. Á., Morales, C., Caro, J., Giménez, M., Borrell, M., & Delgado, E. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01153-4 · Cited by 20
“Regarding the results achieved by both insulins in terms of CGM-based targets, it should be underlined that in neither TIR nor TBR were the recommendations of the ATTD consensus for CGM utilization achieved [38].”
MethodAssociation of time in range with postoperative wound healing in patients with diabetic foot ulcers
Huang, Z., Zhang, H., Huang, Y., Ye, S.-L., Ma, Y., Xin, Y., Chen, X., & Zhao, S. (2021) · International Wound Journal · doi:10.1111/iwj.13725 · Cited by 21
“TIR reflects hypoglycaemia events and blood glucose fluctuations that can provide guidance for glycaemic control.(17) The validity of TIR using sevenpoint testing and the association with risk of development of retinopathy and microalbuminuria in DCCT have been demonstrated.”
BackgroundMoser, O., Sternad, C., Eckstein, M. L., Szadkowska, A., Michalak, A., Mader, J. K., Ziko, H., Elsayed, H., Aberer, F., Sola‐Gazagnes, A., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14609 · Cited by 19
“! 16 (8-28) n = 161 19 (9-35) n = 569 13 (6-23) n = 4495 9 (4-16) n = 1092 9 (4-16) n = 437 <0.”
Díaz-Soto, G., Bahillo-Curieses, P., Jimenez, R., de la Marca, M. D. L. O. N., Gomez, E., Torres, B., Gómez, J. J. L., & de Luis, D. A. (2021) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2021.11.006 · Cited by 24
Gouveri, E., & Παπάνας, Ν. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01257-5 · Cited by 25
“CGM is increasingly used due to its many advantages, namely accuracy and easiness of use, as well as the ability to assess daily variations in glucose [4].”
BackgroundInfluentialGrady, M., Cameron, H., Bhatiker, A., Holt, E., & Schnell, O. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0134 · Cited by 20
“In contrast, our analysis is based on episodic, capillary BG testing with a BGM device, so we chose the term ‘‘readings in range’’ (RIR) to denote BGM readings from 70 to 180 mg/dL, which are the commonly accepted criteria for in range data.(13) Keynote articles based on CGM data highlight that a predicted (estimated)…”
MethodDiaz C., J. L., Fabris, C., Breton, M. D., & Cengiz, E. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0154 · Cited by 19
Flatt, A. J., Chen, E., Peleckis, A. J., DALTON-BAKES, C. V., Nguyen, H.-L., Collins, H. W., Millar, J. S., Gallop, R., & Rickels, M. R. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0103 · Cited by 23
“Nonetheless,CGMdatawerestillcapturedoveronlya 7-dayperiodofrecordingwithconsensusreportsrecomme-ndingatleast14daysofmeasurement 51 to correlate well with 3-month data.”
Oda, T., Satoh, M., Nagasawa, K., et al. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01298-w · Cited by 19
“valuable insights to those provided by traditional parameters [10].”
BackgroundArtificial Intelligence in Efficient Diabetes Care
Khodve, G., & Banerjee, S. (2022) · Current Diabetes Reviews · doi:10.2174/1573399819666220905163940 · Cited by 20
Intelligent Control with Artificial Neural Networks for Automated Insulin Delivery Systems
de Farias, J. L. C. B., & Bessa, W. M. (2022) · Bioengineering · doi:10.3390/bioengineering9110664 · Cited by 24
“It is also important to highlight, for the evaluation of glycemic control, standardized CGM metrics for clinical care [59,60] were used.”
BackgroundMethodInfluentialReal-Time Continuous Glucose Monitoring in the Hospital: A Real-World Experience
Bagsic, S. R. S., Fortmann, A. L., Belasco, R. F., BASTIAN, A., Lohnes, S., Ritko, A. L., Sandoval, H., CHICHMARENKO, M., Soriano, E. C., Talavera, L., et al. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231165982 · Cited by 27
Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes
Conde, A. C., Martín, D. M., Ruíz, R. C., Olmo, M. R. F., Ariño, C. M., Gómez‐Doblas, J. J., Górriz, J. L., Mazón‐Ramos, P., García–Moll, X., Soler, M. J., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12123925 · Cited by 23
Urbano, F., Farella, I., Brunetti, G., & Faienza, M. F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241511980 · Cited by 25
“Therefore, the proposed targets for TIR, TBR, and TAR should be an essential component for CGM data analysis and treatment decisions [48].”
BackgroundMethodInfluentialCambuli, V. M., & Baroni, M. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713139 · Cited by 20
“Recent years have seen exponential growth in the technology of automated insulin delivery systems with the aim of improving the time in range (TIR) until reaching and exceeding the objectives of good compensation [3,59] and glycosylated haemoglobin (HbA1c) [1,3].”
BackgroundRademaker, D., van der Wel, A. W. T., van EEKELEN, R., Voormolen, D. N., de Valk, H. W., Evers, I. M., Mol, B. W., Franx, A., Siegelaar, S. E., van Rijn, B. B., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15276 · Cited by 22
“8,9 Following the introduction for CGM, initially only in type 1 diabetes, CGM is now increasingly being employed in women with type 2 diabetes and gestational diabetes mellitus (GDM).”
MethodSelf-citationElbarbary, N. S., & Ismail, E. A. R. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01184-w · Cited by 20
“Although the changes were statistically significant, the overall outcomes across all ages and genders were well within the recommended guidelines [28] and the traditional gap in control in the younger versus older population [18, 42] is diminished with the AHCL system [40].”
BackgroundMethodCurrent and future therapies to treat impaired awareness of hypoglycemia
Macon, E. L., DEVORE, M. H., Lin, Y. K., MUSIC, M. B., WOOTEN, M., McMullen, C. A., Woodcox, A. M., MARKSBURY, A. R., Beckner, Z., Patel, B. V., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1271814 · Cited by 23
Bezerra, M. F., Neves, C., Neves, J. S., & Carvalho, D. M. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01219-2 · Cited by 26
“Due to the limitations of HbA1c, continuous glucose monitoring (CGM) devices have been recommended as a central tool for managing patients with Type 1 Diabetes (T1D) [9].”
MethodReducing Diabetes Burden in Medtronic's Automated Insulin Delivery Systems
Forlenza, G. P., Dai, Z., Niu, F., & Shin, J. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0459 · Cited by 25
Bahillo-Curieses, P., Fernández-Velasco, P., Pérez-López, P., Martínez, A. M. V., de la Marca, M. D. L. O. N., & Díaz-Soto, G. (2024) · Endocrine · doi:10.1007/s12020-024-03881-6 · Cited by 24
“Subsequently, the International TIR Consensus set control goals for these parameters based on the type of diabetes [3].”
BackgroundMethodInfluentialCichosz, S. L., Olesen, S. S., & Jensen, M. H. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241286907 · Cited by 27
“15,32,33 We defined targets by binary thresholds that have all been recommended as treatment targets in recent CGM consensus guidelines: Hyperglycemia: weeks with TAR (level 2) ≥ 5%.”
Pleus, S., Eichenlaub, M., Boija, E. E., Fokkert, M. J., Hinzmann, R., JENDLE, J. H., Klonoff, D. C., Makris, K., Nichols, J. H., Pemberton, J. S., et al. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241296097 · Cited by 26
Feasibility of a New Approach to Initiate Insulin in Type 2 Diabetes
Aradóttir, T. B., Bengtsson, H. L., Jensen, M. L., Poulsen, N. K., Boiroux, D., Jensen, L. L., Schmidt, S., & Nørgaard, K. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819900240 · Cited by 20
“During the first two weeks, a median (range) of 7% (2-58) of CGM data were missing, whereof one participant was missing more than the 30% consensus criteria.”
BackgroundSelf-citationLower HbA1c targets are associated with better metabolic control
SWEET study group, Loocke, M. V., Battelino, T., Tittel, S. R., Prahalad, P., Gökşen, D., Davis, E. A., & Casteels, K. (2021) · European Journal of Pediatrics · doi:10.1007/s00431-020-03891-2 · Cited by 20
“In a recent prospective study in the UK (DECIDE-study), only clinically well children (without DKA) aged under 17 years with newly diagnosed T1D were randomized to home or hospital management.”
BackgroundInfluentialSelf-citationSustainable Use of a Real-Time Continuous Glucose Monitoring System from 2018 to 2020
van der Linden, J., Welsh, J. B., & Walker, T. C. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0014 · Cited by 19
“The mean fraction of glucose values that were 70 or 54mg/dL was consistently lower than the current international consensus goals for most people with diabetes 11 but was significantly lower during G6 use than during G5 use.”
Ando, Y., Shigiyama, F., Hirose, T., & Kumashiro, N. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13533 · Cited by 19
Reid, L. J., Gibb, F. W., Colhoun, H. M., Wild, S. H., Strachan, M. W. J., Madill, K., Dhillon, B., & Forbes, S. (2021) · Diabetologia · doi:10.1007/s00125-021-05456-w · Cited by 29
Efficient Closed Loop Simulation of Do-It-Yourself Artificial Pancreas Systems
Schmitzer, J., Strobel, C., Blechschmidt, R. A., Tappe, A., & Peuscher, H. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211032249 · Cited by 20
Evolving Use of Continuous Glucose Monitoring Beyond Intensive Insulin Treatment
Wright, E. E., & Subramanian, S. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0191 · Cited by 20
Zivojinovic, A. S. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.105605 · Cited by 22
Arnoriaga‐Rodríguez, M., Leal, Y., Mayneris‐Perxachs, J., Pérez‐Brocal, V., Moyá, A., Ricart, W., Fernández-Balsells, M., & Fernández‐Real, J. M. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad258 · Cited by 20
Rizos, E. C., Markozannes, G., Charitakis, N., Filis, P., Stoimeni, A. E., Nørgaard, K., Ntzani, E. E., & Tsilidis, K. K. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0599 · Cited by 21
Self-citationJakubowska, Z., & Małyszko, J. (2023) · Journal of Nephrology · doi:10.1007/s40620-023-01802-w · Cited by 22
“[36] These recommendations have also been endorsed by the American Association of Clinical Endocri-nologists, the American Diabetes Association, the Association of Diabetes Care and Education Specialists, Diabetes India, the European Association for the Study of Diabetes, the International Society…”
BackgroundMartens, T. W., Willis, H. J., Bergenstal, R. M., Kruger, D. F., French, E. K., & Steenkamp, D. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0579 · Cited by 25
Self-citation
Metadata
- Authors
- Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., Cobelli, C., Dassau, E., DeVries, J. H., Donaghue, K. C., Dovc, K., Doyle, F. J., Garg, S., Grunberger, G., Heller, S., Heinemann, L., Hirsch, I. B., Hovorka, R., Jia, W., Kordonouri, O., Kovatchev, B., Kowalski, A., Laffel, L., Levine, B., Mayorov, A., Mathieu, C., Murphy, H. R., Nimri, R., Nørgaard, K., Parkin, C. G., Renard, E., Rodbard, D., Saboo, B., Schatz, D., Stoner, K., Urakami, T., Weinzimer, S. A., & Phillip, M.
- Affiliations
- University of Ljubljana (SI)
- Kinderkrankenhaus auf der Bult (DE)
- Park Nicollet Health Services (US)
- King's College London (GB)
- Jaeb Center for Health Research (US)
- Vita-Salute San Raffaele University (IT)
- Stanford Medicine (US)
- American Diabetes Association (US)
- Close Concerns (United States) (US)
- University of Padua (IT)
- Harvard University (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- The University of Sydney (AU)
- Department of Pediatric Endocrinology, Diabetes and Metabolism, University Children’s Hospital, University Medical Centre Ljubljana, and Faculty of Medicine, University of Ljubljana, Slovenia
- University of Colorado Denver (US)
- Grunberger Diabetes Institute (US)
- University of Sheffield (GB)
- Science Consulting in Diabetes, Neuss, Germany
- University of Washington (US)
- University of Cambridge (GB)
- Shanghai Jiao Tong University (CN)
- University of Virginia (US)
- Breakthrough T1D (US)
- Joslin Diabetes Center (US)
- Endocrinology Research Center (RU)
- KU Leuven (BE)
- University of East Anglia (GB)
- Schneider Children's Medical Center (IL)
- Steno Diabetes Center Copenhagen (DK)
- CGParkin Communications, Inc., Henderson, NV
- Department of Endocrinology, Diabetes, and Nutrition, Montpellier University Hospital; Institute of Functional Genomics, University of Montpellier; and INSERM Clinical Investigation Centre, Montpellier, France
- Biomedical Informatics Consultants LLC, Potomac, MD
- DiaCare, Ahmedabad, Gujarat, India
- University of Florida (US)
- dQ&A Market Research, Inc., San Francisco, CA
- Nihon University (JP)
- Yale University (US)
- Tel Aviv University (IL)
- Corresponding author
- Battelino, Tadej
- ORCID
- Battelino, Tadej
- Danne, Thomas
- Bergenstal, Richard M.
- Amiel, Stephanie A.
- Beck, Roy
- Biester, Torben
- Bosi, Emanuele
- Buckingham, Bruce A.
- Cefalu, William T.
- Close, Kelly L.
- Cobelli, Claudio
- Dassau, Eyal
- DeVries, J. Hans
- Donaghue, Kim C.
- Doyle, Francis J.
- Garg, Satish
- Grunberger, George
- Heller, Simon
- Heinemann, Lutz
- Hirsch, Irl B.
- Hovorka, Roman
- Jia, Weiping
- Kordonouri, Olga
- Kovatchev, Boris
- Kowalski, Aaron
- Laffel, Lori
- Levine, Brian
- Mayorov, Alexander
- Mathieu, Chantal
- Murphy, Helen R.
- Nimri, Revital
- Nørgaard, Kirsten
- Parkin, Christopher G.
- Renard, Eric
- Rodbard, David
- Saboo, Banshi
- Schatz, Desmond
- Stoner, Keaton
- Urakami, Tatsuiko
- Weinzimer, Stuart A.
- Phillip, Moshe
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-06-08
- Volume
- 42
- Issue
- 8
- Pages
- 1593-1603
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC6973648
- OpenAlex
- W2948261890
- Cited by
- 4,237
- References
- 96
- Citations by year
- 2026: 716 · 2025: 649 · 2024: 655 · 2023: 575 · 2022: 619 · 2021: 556 · 2020: 398 · 2019: 61
- FWCI
- 215.44
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- UEA Digital Repository (University of East Anglia) (acceptedVersion)
- Pure Amsterdam UMC (acceptedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Lirias (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Leona M. and Harry B. Helmsley Charitable Trust
- University of Virginia
- Insulet Corporation
- MannKind Corporation
- Dexcom
- OPKO Health
- Steno Diabetes Center Copenhagen (SDCC 3.E Technology)
- National Institute for Health and Care Research (NF-SI-0515-10079, CDF-2013-06-035, 16/35/01)
- Universiteit van Amsterdam
- KU Leuven
- Novo Nordisk
- Roche Diabetes Care
- National Institutes of Health (UL1TR001863)
- U.S. Food and Drug Administration
- Abbott Diabetes Care
- National Cancer Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- continuous glucose monitoring, time in range, glycemic targets, diabetes management, clinical guidelines
- MeSH terms
- Data Accuracy, Blood Glucose, Data Interpretation, Statistical, Diabetes Mellitus, Glycated Hemoglobin, Humans, Patient Care Planning, Reference Values, Time Factors, Blood Glucose Self-Monitoring, Practice Guidelines as Topic, Internationality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.